论文部分内容阅读
9名男性健康自愿受试者采用三交叉单剂口服国产氛罗沙星片剂、胶囊和进口氟罗沙星片剂各400mg的药代动力学参数比较。血、尿药浓度用HPLC检测．结果表明：体内过程符合一室模型，主要药代动力学参数分别为：AUC：82.30±14．30、81．13±8．45与83．92±14.27h·mg／L；Cmax：4．71±0．83、4．67±0．51与4．86±0．89mg／L；Tmax：1．88±0．44、1．90±0．39与1．92±0．23h；T1／2ke：11．02±0．96、10．93±0．68与10．86±0．82h；V／F（c）：79．08±13．31、78.42±8．70与76．39±12．93L；Cl／F：5．00±0．98、4．98±0．52与4．88±0．73L／h。服药48h的尿中原型药排出率分别为给药量的57．4％，55．9％和60．7％。国产氧罗沙星片剂和胶囊口服后药物动力学参数与进口片剂相仿．其相对生物利用及分别为98.07％与96．68％。
Nine male volunteers were randomized to three crossover oral oral salicyofloxacin tablets, capsules and imported fleroxacin tablets 400mg pharmacokinetic parameters. Blood, urine concentration was detected by HPLC. The results showed that the in vivo process accorded with the one-compartment model. The main pharmacokinetic parameters were as follows: AUC: 82.30 ± 14.30, 81.13 ± 8.45 and 83.92 ± 14.27 h · mg / L, respectively; Cmax: 4. 71 ± 0.83, 4.67 ± 0.51 and 4.86 ± 0.89 mg / L; Tmax: 1.88 ± 0.44, 1.90 ± 0.39 and 1.92 ± 0.23 h; T1 / 2ke: 11.02 ± 0.96, 10.93 ± 0.68 and 10.86 ± 0.82 h; V / F (c): 79.08 ± 13.31, 78.42 ± 8.70 and 76 .39 ± 12.93 L; Cl / F: 5.00 ± 0.98, 4.98 ± 0.52 and 4.88 ± 0.73 L / h. 48h urinary prototyping drug discharge rates were 57.4%, 55.9% and 60.7%. After oral administration of oxyrosedoxin tablets and capsules pharmacokinetic parameters and imported tablets similar. The relative bioavailability was 98.07% and 96.68% respectively.